Affairs of the Heart: Innovation in Cardiovascular Research and Development

P. Honig, Andre Terzic

Research output: Contribution to journalEditorial

5 Citations (Scopus)

Abstract

Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.

Original languageEnglish (US)
Pages (from-to)162-168
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number2
DOIs
StatePublished - Aug 1 2017

Fingerprint

Research
Industry
Cardiovascular Diseases
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Affairs of the Heart : Innovation in Cardiovascular Research and Development. / Honig, P.; Terzic, Andre.

In: Clinical Pharmacology and Therapeutics, Vol. 102, No. 2, 01.08.2017, p. 162-168.

Research output: Contribution to journalEditorial

@article{c84fbd10b3d14e119eed034525ba6af8,
title = "Affairs of the Heart: Innovation in Cardiovascular Research and Development",
abstract = "Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.",
author = "P. Honig and Andre Terzic",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/cpt.737",
language = "English (US)",
volume = "102",
pages = "162--168",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Affairs of the Heart

T2 - Innovation in Cardiovascular Research and Development

AU - Honig, P.

AU - Terzic, Andre

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.

AB - Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.

UR - http://www.scopus.com/inward/record.url?scp=85024379270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024379270&partnerID=8YFLogxK

U2 - 10.1002/cpt.737

DO - 10.1002/cpt.737

M3 - Editorial

C2 - 28718903

AN - SCOPUS:85024379270

VL - 102

SP - 162

EP - 168

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -